Shareholder Alert: Robbins LLP Announces Correvio Pharma Corp. (CORV) Sued for Misleading Shareholders
16 Dezembro 2019 - 7:36PM
Business Wire
Shareholder rights law firm Robbins LLP announces that a
purchaser of Correvio Pharma Corp. (NASDAQ: CORV) filed a class
action complaint for alleged violations of the Securities Exchange
Act of 1934 between October 23, 2018 and December 5, 2019. Correvio
is a specialty pharmaceutical company that engages in developing
therapeutics worldwide. The Company's brand portfolio includes
Brinavess, used for the rapid conversion of recent onset atrial
fibrillation ("AF") to sinus rhythm.
If you suffered a loss as a result of Correvio's misconduct,
click here.
Correvio Pharma Corp. (CORV) Accused of Misleading
Shareholders
According to the complaint, during Correvio's development of
Brinavess, safety concerns led the U.S. Food and Drug
Administration ("FDA") to decline approval for Brinavess and
mandate a clinical hold on the Brinavess program following the
death of a patient who had been administered the drug during one of
its clinical trials. Then, in October 2018, Correvio announced its
intention to resubmit a New Drug Application ("NDA") to the FDA for
recent onset AF supported by additional purported safety data that
the Company had accumulated. On July 25, 2019, Correvio announced
that the FDA had accepted the resubmitted NDA. Contrary to
Correvio's representations, on December 6, 2019, the FDA announced
that it did not believe the drug's benefits outweighed its risks,
specifically highlighting "serious liabilities" associated with
Brinavess, including even death. Consequently, on December 10,
2019, the FDA voted against approval of the NDA. On this news,
Correvio shares fell 67% to close at $0.46 per share. The stock
continues to decline.
Correvio Pharma Corp. (CORV) Shareholders Have Legal
Options
Contact us to learn more: Leo Kandinov (800) 350-6003
lkandinov@robbinsllp.com Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional
investors in shareholder derivative and securities class action
lawsuits, and has helped its clients realize more than $1 billion
of value for themselves and the companies in which they have
invested. Click here to receive free alerts from Stock Watch when
companies engage in wrongdoing.
Attorney Advertising. Past results do not guarantee a similar
outcome.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191216005821/en/
Leo Kandinov Robbins LLP 5040 Shoreham Place San Diego, CA 92122
lkandinov@robbinsllp.com (619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com
Correvio Pharma (NASDAQ:CORV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Correvio Pharma (NASDAQ:CORV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024